2022年英国风湿病学会《孕期和哺乳期用药-免疫调节抗风湿药物和皮质激素类药物》指南解读OA
Understanding of"Prescribing drugs in pregnancy and breastfeeding:immunomodulatory anti-rheumatic drugs and corticosteroids"guideline by the British Society of Rheumatology in 2022
2022年11月2日英国风湿病学会(BSR)发布了《孕期和哺乳期用药-免疫调节抗风湿药物和皮质激素类药物》指南,该指南针对孕期和哺乳期处方抗风湿药物提供指导建议,内容包括抗疟药、糖皮质激素、传统合成的抗风湿药物(csDMARDs)和免疫制剂、生物制剂(bDMARDs)和靶向制剂(tsDMARDs)在妊娠期、哺乳期的安全性及对父亲用药的建议,补充了 bDMARDs和tsDMARDs的推荐意见,旨在为医务人员使用该类药物提供依据.
The British Society for Rheumatology(BSR)published"Prescribing drugs in pregnancy and breastfeeding:immunomodulatory anti-rheumatic drugs and corticosteroids"guideline on November 2,2022,the guideline provides the guidance suggestion on prescribing antirheumatic drugs during pregnant period and lactation period,the contents include the safety of antimalarials;corticosteroids;conventional synthetic DMARDs(csDMARDs)and immunosuppressive therapies;biologic DMARDs(bDMARDs);and targeted syn-thetic DMARDs(tsDMARDs)during pregnant period and lactation period,the recommendations for father medication,and replenish the recommendations for bMDARDs and tsDMARDs in order to provide a basis for the medical staff to use these kinds of drugs.
姚蓉;董晓静
重庆医科大学附属第二医院妇产科,重庆 400010
中医学
风湿免疫病妊娠期哺乳期父亲药物安全性
Rheumatic immunePregnancyBreastfeedingFatherDrugsSafety
《现代医药卫生》 2024 (001)
1-9 / 9
国家儿童健康与疾病临床医学研究中心临床医学研究一般项目(NCRCCHD-2020-GP-16).
评论